Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 35Terminated 5Unknown 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 2Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Pancreatic Neoplasms 23Breast Neoplasms 19Carcinoma, Non-Small-Cell Lung 12Neoplasm Metastasis 11Triple Negative Breast Neoplasms 8Neoplasms 5Small Cell Lung Carcinoma 4Sarcoma 4Ovarian Neoplasms 4Lymphoma, Non-Hodgkin 4Lung Neoplasms 4Hodgkin Disease 4Breast Neoplasms, Male 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Multiple Myeloma 3Urinary Bladder Neoplasms 2Recurrence 2Prostatic Neoplasms 2Melanoma 2Lymphoma 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Pancreatic Ductal 2Carcinoma 2Uterine Cervical Neoplasms 1Thrombocytosis 1Stages II-III Breast Cancer 1Spinal Cord Compression 1Rectal Neoplasms 1

Interventions

Gemcitabine 34pembrolizumab 27Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × Neoplasms × Albumin-Bound Paclitaxel × Clear all
NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

Seagen Inc.

Phase 1 Terminated
159 enrolled
DermatologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT03524898 2022-09-28

NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma

Swiss Cancer Institute

Phase 1/2 Terminated
39 enrolled
Sarcoma

Neoplasms, Sarcoma

NCT02476955 2020-09-30

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Terminated
41 enrolled
BreastGynecologic

Uterine Cervical Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT01376310 2019-02-19

GSK1120212 Rollover Study

Novartis

Phase 2 Terminated
159 enrolled 9 charts
Tumor-Agnostic

Neoplasms

NCT02241551 2018-07-26

Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

University of Pittsburgh

Phase 2 Terminated
2 enrolled 7 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡